SWOG S1404: A phase III randomized trial comparing standard of care adjuvant therapy to pembrolizumab in patients with high risk resected melanoma.

被引：13
|
作者：
Grossmann, Kenneth F.
Othus, Megan
Tarhini, Ahmad A.
Patel, Sapna Pradyuman
Moon, James
Sondak, Vernon K.
Kirkwood, John M.
Ribas, Antoni
机构：
[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[2] SWOG Stat Ctr, Seattle, WA USA
[3] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Southwest Oncol Grp, Ctr Stat, Seattle, WA USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[7] Univ Pittsburgh, Dept Med, Med Ctr, Pittsburgh, PA USA
[8] UCLA Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e21032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21032
引用
收藏
页数：2
相关论文
共 50 条
  • [1] SWOG S1404: A phase III randomized trial comparing high dose interferon to pembrolizumab in patients with high risk resected melanoma.
    Grossmann, Kenneth F.
    Othus, Megan
    Tarhini, Ahmad A.
    Patel, Sapna Pradyuman
    Kirkwood, John M.
    Moon, James
    Sondak, Vernon K.
    Ribas, Antoni
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] A phase Ill randomized trial comparing FDA approved standard of care adjuvant therapy to one year of pembrolizumab in patients with high risk resected melanoma. SWOG 1404
    Grossmann, Kenneth F.
    Sondak, Vernon K.
    Othus, Megan
    Tarhini, Ahmad
    Patel, Sapna
    Kirkwood, John M.
    Ribas, Antoni
    Moon, James
    [J]. CANCER RESEARCH, 2016, 76
  • [3] Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial
    Unger, Joseph M.
    Darke, Amy
    Othus, Megan
    Truong, Thach-Giao
    Khushalani, Nikhil
    Kendra, Kari
    Lewis, Karl D.
    Faller, Bryan
    Funchain, Pauline
    Buchbinder, Elizabeth I.
    Tarhini, Ahmad A.
    Kirkwood, John M.
    Sharon, Elad
    Sondak, Vernon
    Guild, Samantha R.
    Grossmann, Kenneth
    Ribas, Antoni
    Patel, Sapna P.
    [J]. JAMA ONCOLOGY, 2023, 9 (02) : 251 - 260
  • [4] Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.
    Grossmann, Kenneth F.
    Othus, Megan
    Patel, Sapna Pradyuman
    Tarhini, Ahmad A.
    Sondak, Vernon K.
    Petrella, Teresa M.
    Truong, Thach-Giao
    Khushalani, Nikhil I.
    Cohen, Justine Vanessa
    Buchbinder, Elizabeth Iannotti
    Kendra, Kari Lynn
    Funchain, Pauline
    Lewis, Karl D.
    Chmielowski, Bartosz
    Li, Hongli
    Moon, James
    Gunturu, Krishna Soujanya
    Eroglu, Zeynep
    Kirkwood, John M.
    Ribas, Antoni
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Quality of life (QOL) endpoints from the phase III intergroup S1404 adjuvant melanoma trial
    Patel, S.
    Unger, J. M.
    Othus, M.
    Darke, A.
    Tarhini, A. A.
    Kirkwood, J. M.
    Sharon, E.
    Sondak, V.
    Ribas, A.
    Grossmann, K. F.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S890 - S890
  • [6] Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma.
    Luke, Jason J.
    Ascierto, Paolo Antonio
    Carlino, Matteo S.
    Eggermont, Alexander M. M.
    Grob, Jean-Jacques
    Hauschild, Axel
    Kirkwood, John M.
    Long, Georgina V.
    Mohr, Peter
    Robert, Caroline
    Gershenwald, Jeffrey E.
    Poklepovic, Andrew Stewart
    Ross, Merrick I.
    Scolyer, Richard A.
    Yoon, Charles
    Anderson, James R.
    Ahsan, Sama
    Ibrahim, Nageatte
    Sondak, Vernon K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [7] S1801: A randomized phase II trial of adjuvant versus neoadjuvant pembrolizumab (PEM) for melanoma.
    Patel, Sapna Pradyuman
    Othus, Megan
    Moon, James
    Tetzlaff, Michael T.
    Buchbinder, Elizabeth Iannotti
    Sondak, Vernon K.
    Lowe, Michael C.
    Campos, Danae
    Sharon, Elad
    Korde, Larissa A.
    Carson, William Edgar
    Ribas, Antoni
    Grossmann, Kenneth F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Association between circulating tumor DNA (ctDNA) and recurrence-free survival (RFS) in patients (pts) with resected stage III melanoma: An exploratory analysis of SWOG S1404
    LaPelusa, Michael Brian
    Marcano, David
    Othus, Megan
    Grossmann, Allie
    Aushev, Vasily N.
    Sridhar, Bharat
    Renner, Derrick
    Sethi, Himanshu
    Liu, Minetta C.
    Tarhini, Ahmad A.
    Kirkwood, John M.
    Grossmann, Kenneth F.
    Moon, James
    Li, Hongli
    Mashru, Sandeep H.
    Khushalani, Nikhil I.
    Sharon, Elad
    Korde, Larissa A.
    Ribas, Antoni
    Patel, Sapna Pradyuman
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
    Ribas, Antoni
    Kefford, Richard
    Marshall, Margaret A.
    Punt, Cornelis J. A.
    Haanen, John B.
    Marmol, Maribel
    Garbe, Claus
    Gogas, Helen
    Schachter, Jacob
    Linette, Gerald
    Lorigan, Paul
    Kendra, Kari L.
    Maio, Michele
    Trefzer, Uwe
    Smylie, Michael
    McArthur, Grant A.
    Dreno, Brigitte
    Nathan, Paul D.
    Mackiewicz, Jacek
    Kirkwood, John M.
    Gomez-Navarro, Jesus
    Huang, Bo
    Pavlov, Dmitri
    Hauschild, Axel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (05) : 616 - 622
  • [10] Phase III randomized, multicenter trial comparing high-dose IFN-a2b with temozolomide plus cisplatin as adjuvant therapy for resected mucosal melanoma
    Lian, Bin
    Cui, Chuanliang
    Song, Xin
    Zhang, Xiaoshi
    Wu, Di
    Si, Lu
    Chi, Zhihong
    Sheng, Xinan
    Kong, Yan
    Mao, Li Li
    Zhou, Li
    Wang, Xuan
    Tang, Bixia
    Yan, Xieqiao
    Li, Siming
    Li, Dan
    Dai, Jie
    Bai, Xue
    Li, CaiLi
    Guo, Jun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345